- Home
- MCRB
as 03-25-2025 12:34pm EST
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 141.9M | IPO Year: | 2015 |
| Target Price: | $4.00 | AVG Volume (30 days): | 858.8K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $1.53 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -51.35% |
Stock Insider Trading Activity of Seres Therapeutics Inc. (MCRB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Teresa L. | MCRB | See Remarks | Feb 15 '25 | Sell | $0.81 | 3,338 | $2,704.45 | 97,536 | |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Feb 15 '25 | Sell | $0.81 | 4,300 | $3,485.15 | 142,456 | |
| von Moltke Lisa | MCRB | See Remarks | Feb 15 '25 | Sell | $0.81 | 4,416 | $3,579.17 | 39,875 | |
| Shaff Eric D. | MCRB | CEO and President | Feb 15 '25 | Sell | $0.81 | 12,726 | $10,314.42 | 192,039 | |
| Henn Matthew R. | MCRB | See Remarks | Feb 15 '25 | Sell | $0.81 | 3,953 | $3,203.51 | 84,443 |
Latest Seres Therapeutics Inc. News
MCRB Breaking Stock News: Dive into MCRB Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 days ago
Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?
GuruFocus.com
12 days ago
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ...
Thomson Reuters StreetEvents
12 days ago
Q4 2024 Seres Therapeutics Inc Earnings Call
GlobeNewswire
13 days ago
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire
22 days ago
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
GlobeNewswire
23 days ago
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
MT Newswires
2 months ago
Seres Therapeutics Receives First of 2 Installments Related to VOWST Sale
GlobeNewswire
2 months ago
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
Compare MCRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.